New bone graft mix shows promise for dental implants in severe jaw atrophy
NCT ID NCT07186166
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed study tested a bone graft mixture (30% hydroxyapatite and 70% beta-tricalcium phosphate) combined with platelet-rich fibrin in 42 patients with severe jaw bone loss (less than 4 mm height). After 6 months, core biopsies showed new bone formation, allowing dental implant placement. The study suggests this graft may help patients who otherwise lack enough bone for implants.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bone graft mixture (30% hydroxyapatite and 70% beta-tricalcium phosphate) combined with platelet-rich fibrin
- What this could lead to
- If successful, this approach could improve dental implant success in patients with severe jaw bone loss.
- What could go wrong
- This is a small, single-arm study with no comparison group. Results may not apply to all patients, and long-term implant success is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Jan 2022
- Finished
-
Feb 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a residual bone height ≤4 mm * minimum prosthetic space of 5 mm Exclusion Criteria: * Patients with acute or chronic maxillary sinusitis, bleeding disorders, diabetes mellitus, bone metabolic diseases, periodontal disease, or malignancies were excluded. * taking medications that could affect bone metabolism or hemostasis * Smokers and pregnant women were also excluded from the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Implant site reaction are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Can Tho University of Medicine and Pharmacy
Can Tho, 90000, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.